Read key research highlights that will be presented at the 2018 ASCO Annual Meeting, including monitoring symptoms with technology, screening and genomic testing for lung cancer, and new treatment regimens for breast cancer and T-cell leukemia and lymphoma.
People who have HIV are at a higher risk for developing some cancers. Dr. Ramya Ramaswami shares what you need to know about cancer prevention and treatment if you’re living with the virus.
In this podcast, Cancer.Net Specialty Editor Dr. Timothy Gilligan discusses some of the quality-of-life research featured at the 2018 Cancer Survivorship Symposium: Advancing Care and Research.
The 2018 Clinical Cancer Advances report of the American Society of Clinical Oncology has crowned an adoptive cell immunotherapy as its Advance of the Year. What is this innovative cancer treatment? What are the risks and benefits?
In this podcast, Cancer.Net Associate Editor Dr. Michael Williams describes lymphoma research advances presented at the American Society of Hematology Annual Meeting.
The 2017 Clinical Cancer Advances report of the American Society of Clinical Oncology has announced that the Advance of the Year is Immunotherapy 2.0. Why 2.0? Because the role of immunotherapy in cancer care is expanding, and oncologists are learning how to use it more effectively.
In this podcast, Dr. Michael E. Williams reports on the highlights from the 2016 American Society of Hematology Annual Meeting.
These studies from the ASCO Annual Meeting show some of the newest thoughts and latest advances in using immunotherapy and targeted therapy to treat bladder, stomach, and lung cancers.
Michael E. Williams, MD, ScM discusses highlights from the recent American Society of Hematology Annual Meeting. Listen in to hear what’s new in treatment for blood cancers.
This year, President Obama has focused attention on treatments and tools that help doctors tailor medical care for individual patients. Research presented at the 2015 ASCO Annual Meeting shows how targeted therapies can be used to improve the care of people with a number of different types of blood cancer.